Currently operating 43 dispensaries across the US, Curaleaf Holdings, Inc. (CSE: CURA; OTCQX: CURLF) capped the week by opening two new locations in Florida.
Previously serving as a product fulfillment center, the Gainesville site has now been converted into a full service dispensary with an additional focus on cannabis education efforts. The store includes a meeting space to be used the local community where Curaleaf will host monthly gatherings of patients and medical staff.
The second dispensary in Miami is also notable for offering a medical marijuana drive through service. Originally starting with the company’s existing Palm Harbor dispensary last year, Curaleaf is aiming to expand that service concept to more locations.
Chief Executive Officer Joe Lusardi commented on the motivation behind the Miami store’s drive through facility:
Smokable medical marijuana was only legalized in Florida earlier this week when Governor Ron DeSantis signed legislation repealing a former ban.
That sudden legalization has resulting in licensed producers such as Curaleaf and Trulieve (OTCMKTS: TCNNF) rushing to offer whole flower products to patients across the state. It was widely reported in Florida local news sources that Trulieve sold the state’s first legal medical whole flower cannabis at the company’s Tallahassee dispensary yesterday.
Aside from opening new dispensaries across the nation, Curaleaf’s stock price shot up significantly earlier this week after the company announced it would be supplying hemp-based CBD products to the nationwide CVS pharmacy chain.
Lotions, creams, and sprays containing hemp-derived CBD will appear in CVS store aisles across four states next week, with additional CBD distributed deals expected to be revealed in the coming months.
Curaleaf additionally announced a deal earlier this week to acquire Nevada-based cultivation company Acres Cannabis for $45 million in a bid to increase vertical integration in the state.
A full breakdown of Curaleaf’s latest quarterly financial reports, as well as the potential impact of the CVS deal, can be read over here.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.